Literature DB >> 31613176

Translational readthrough of GLA nonsense mutations suggests dominant-negative effects exerted by the interaction of wild-type and missense variants.

Silvia Lombardi1, Mattia Ferrarese1, Saverio Marchi2, Paolo Pinton2, Mirko Pinotti1, Francesco Bernardi1, Alessio Branchini1.   

Abstract

Nonsense mutations are relatively frequent in the rare X-linked lysosomal α-galactosidase A (α-Gal) deficiency (Fabry disease; FD), but have been poorly investigated. Here, we evaluated the responsiveness of a wide panel (n = 14) of GLA premature termination codons (PTCs) to the RNA-based approach of drug-induced readthrough through expression of recombinant α-Gal (rGal) nonsense and missense variants.We identified four high-responders to the readthrough-inducing aminoglycoside G418 in terms of full-length protein (C56X/W209X, ≥10% of wild-type rGal) and/or activity (Q119X/W209X/Q321X, ~5-7%), resulting in normal (Q119X/Q321X) or reduced (C56X, 0.27 ± 0.11; W209X, 0.35 ± 0.1) specific activity.To provide mechanistic insights we investigated the predicted amino acid substitutions mediated by readthrough (W209C/R, C56W/R), which resulted in correct lysosomal localization and appreciable protein/activity levels for the W209C/R variants. Differently, the C56W/R variants, albeit appreciably produced and localized into lysosomes, were inactive, thus indicating detrimental effects of substitutions at this position.Noticeably, when co-expressed with the functional W209C or W209R variants, the wild-type rGal displayed a reduced specific activity (0.5 ± 0.2 and 0.6 ± 0.2, respectively) that, considering the dimeric features of the α-Gal enzyme, suggested dominant-negative effects of missense variants through their interaction with the wild-type.Overall, we provide a novel mechanism through which amino acids inserted during readthrough might impact on the functional protein output. Our findings may also have implications for the interpretation of pathological phenotypes in heterozygous FD females, and for other human disorders involving dimeric or oligomeric proteins.

Entities:  

Keywords:  Nonsense mutations; fabry disease; lysosomal disorders; translational readthrough

Year:  2019        PMID: 31613176      PMCID: PMC6973320          DOI: 10.1080/15476286.2019.1676115

Source DB:  PubMed          Journal:  RNA Biol        ISSN: 1547-6286            Impact factor:   4.652


  45 in total

1.  α-Galactosidase aggregation is a determinant of pharmacological chaperone efficacy on Fabry disease mutants.

Authors:  Aleksandra Siekierska; Greet De Baets; Joke Reumers; Rodrigo Gallardo; Stanislav Rudyak; Kerensa Broersen; Jose Couceiro; Joost Van Durme; Joost Schymkowitz; Frederic Rousseau
Journal:  J Biol Chem       Date:  2012-07-06       Impact factor: 5.157

2.  Heterozygous Fabry women are not just carriers, but have a significant burden of disease and impaired quality of life.

Authors:  Raymond Y Wang; Alicia Lelis; James Mirocha; William R Wilcox
Journal:  Genet Med       Date:  2007-01       Impact factor: 8.822

3.  Nonsense suppression by near-cognate tRNAs employs alternative base pairing at codon positions 1 and 3.

Authors:  Bijoyita Roy; John D Leszyk; David A Mangus; Allan Jacobson
Journal:  Proc Natl Acad Sci U S A       Date:  2015-03-02       Impact factor: 11.205

4.  A carboxy-terminal truncation of human alpha-galactosidase A in a heterozygous female with Fabry disease and modification of the enzymatic activity by the carboxy-terminal domain. Increased, reduced, or absent enzyme activity depending on number of amino acid residues deleted.

Authors:  N Miyamura; E Araki; K Matsuda; R Yoshimura; N Furukawa; K Tsuruzoe; T Shirotani; H Kishikawa; K Yamaguchi; M Shichiri
Journal:  J Clin Invest       Date:  1996-10-15       Impact factor: 14.808

Review 5.  Narrative review: Fabry disease.

Authors:  Joe T R Clarke
Journal:  Ann Intern Med       Date:  2007-03-20       Impact factor: 25.391

6.  Synthesis and processing of alpha-galactosidase A in human fibroblasts. Evidence for different mutations in Fabry disease.

Authors:  P Lemansky; D F Bishop; R J Desnick; A Hasilik; K von Figura
Journal:  J Biol Chem       Date:  1987-02-15       Impact factor: 5.157

7.  The molecular defect leading to Fabry disease: structure of human alpha-galactosidase.

Authors:  Scott C Garman; David N Garboczi
Journal:  J Mol Biol       Date:  2004-03-19       Impact factor: 5.469

8.  Structure-function relationships in alpha-galactosidase A.

Authors:  Scott C Garman
Journal:  Acta Paediatr       Date:  2007-04       Impact factor: 2.299

9.  Secretion of wild-type factor IX upon readthrough over F9 pre-peptide nonsense mutations causing hemophilia B.

Authors:  Mattia Ferrarese; Maria Francesca Testa; Dario Balestra; Francesco Bernardi; Mirko Pinotti; Alessio Branchini
Journal:  Hum Mutat       Date:  2018-02-17       Impact factor: 4.878

10.  Functional characterisation of alpha-galactosidase a mutations as a basis for a new classification system in fabry disease.

Authors:  Jan Lukas; Anne-Katrin Giese; Arseni Markoff; Ulrike Grittner; Ed Kolodny; Hermann Mascher; Karl J Lackner; Wolfgang Meyer; Phillip Wree; Viatcheslav Saviouk; Arndt Rolfs
Journal:  PLoS Genet       Date:  2013-08-01       Impact factor: 5.917

View more
  2 in total

1.  AAV-delivered suppressor tRNA overcomes a nonsense mutation in mice.

Authors:  Jiaming Wang; Yue Zhang; Craig A Mendonca; Onur Yukselen; Khaja Muneeruddin; Lingzhi Ren; Jialing Liang; Chen Zhou; Jun Xie; Jia Li; Zhong Jiang; Alper Kucukural; Scott A Shaffer; Guangping Gao; Dan Wang
Journal:  Nature       Date:  2022-03-23       Impact factor: 69.504

Review 2.  Molecular Insights into Determinants of Translational Readthrough and Implications for Nonsense Suppression Approaches.

Authors:  Silvia Lombardi; Maria Francesca Testa; Mirko Pinotti; Alessio Branchini
Journal:  Int J Mol Sci       Date:  2020-12-11       Impact factor: 5.923

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.